欢迎使用我们的服务!
限时优惠,立即购买享受折扣
24小时客服在线,随时为您服务
优质产品,值得信赖

Novo Nordisk Sues Lilly Over GLP-1 Ads, Citing Inadequate Disclaimers On Dose Comparisons

Novo Nordisk Sues Lilly Over GLP-1 Ads, Citing Inadequate Disclaimers On Dose Comparisons

Broadcast and social media ads for Zepbound and Mounjaro are false because they cite outdated clinical trials that compare the highest doses of Lilly’s medicines to lower doses of Novo’s Wegovy and Ozempic, the lawsuit states.